NASDAQ · CAPR
Healthcare · Biotechnology
$8.30
Up+$0.07 (+0.84%)
Updated Sep 12, 2026, 1:26 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
CAPR closed at $8.30 after 19 trading sessions, up 24.81% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $8.575 | $8.70 | $8.1815 | $8.30 | 2.92M |
| Sep 9, 2026 | $9.08 | $9.27 | $8.60 | $8.64 | 2.75M |
| Sep 8, 2026 | $9.15 | $9.4876 | $8.81 | $9.06 | 2.73M |
| Sep 4, 2026 | $9.40 | $9.81 | $9.26 | $9.40 | 2.56M |
| Sep 3, 2026 | $9.83 | $9.93 | $9.14 | $9.28 | 4.06M |
| Sep 2, 2026 | $10.07 | $10.65 | $9.60 | $9.89 | 5.17M |
| Sep 1, 2026 | $10.77 | $11.00 | $9.85 | $10.01 | 6.31M |
| Aug 31, 2026 | $9.495 | $10.27 | $9.065 | $9.91 | 4.56M |
| Aug 28, 2026 | $9.73 | $10.20 | $9.47 | $9.59 | 5.19M |
| Aug 27, 2026 | $9.19 | $10.61 | $8.90 | $10.06 | 12.05M |
| Aug 26, 2026 | $8.29 | $9.88 | $8.05 | $9.36 | 12.04M |
| Aug 25, 2026 | $7.25 | $8.60 | $7.25 | $8.29 | 17.63M |
| Aug 24, 2026 | $8.03 | $8.03 | $6.34 | $6.80 | 20.09M |
| Aug 21, 2026 | $6.81 | $7.08 | $6.01 | $6.29 | 8.36M |
| Aug 20, 2026 | $7.66 | $7.82 | $6.83 | $6.835 | 8.11M |
| Aug 19, 2026 | $7.19 | $7.99 | $7.14 | $7.98 | 8.57M |
| Aug 18, 2026 | $7.50 | $8.29 | $6.7641 | $7.08 | 8.54M |
| Aug 17, 2026 | $6.87 | $7.59 | $6.59 | $7.45 | 19.22M |
| Aug 14, 2026 | $7.66 | $8.15 | $6.04 | $6.65 | 66.33M |
The latest Smart Investors Daily articles mentioning CAPR.
CAPR research
Company profile and research snapshot.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | Piper Sandler | Overweight | — |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | Jones Trading | Hold | — |
| Jul 30, 2026 | Piper Sandler | Neutral | — |
| Jul 30, 2026 | Cantor Fitzgerald | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 5, 2026
Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company. The submission supports a refined proposed indication focused on upper limb function, which […]
SeekingAlpha · Sep 3, 2026
Yahoo · Sep 1, 2026
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and
Benzinga · Sep 1, 2026
Piper Sandler analyst Edward Tenthoff upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $2 to $25.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAPR.
